C ognitive impairment in the context of stroke or transient ischemic attack (TIA) is a prototype of vascular cognitive impairment (VCI). Our recent in vivo study using carbon-11-labeled Pittsburgh compound B ( 11 C-PiB) positron emission tomography (PET) found that ≈30% of subjects with poststroke/TIA cognitive impairment harbored Alzheimer's pathology.
C ognitive impairment in the context of stroke or transient ischemic attack (TIA) is a prototype of vascular cognitive impairment (VCI). Our recent in vivo study using carbon-11-labeled Pittsburgh compound B ( 11 C-PiB) positron emission tomography (PET) found that ≈30% of subjects with poststroke/TIA cognitive impairment harbored Alzheimer's pathology. 1 Although some studies suggested that in patients with clinical Alzheimer's disease (AD), comorbid cerebrovascular disease was associated with a more rapid cognitive decline, 2, 3 it is still unknown whether concurrent presence of Alzheimer's pathology is associated with a faster cognitive deterioration in patients with poststroke/TIA cognitive impairment.
In this study, we compared the longitudinal cognitive changes between VCI patients with and without AD-like amyloid-beta (Aβ) deposition measured using STRIDE study, we recruited consecutive stroke/TIA subjects admitted to the acute stroke unit of a University Affiliated Hospital during a 2-year period (2009) (2010) . We aimed to study the rate and predictors of cognitive decline over a period of 5 years in stroke/TIA patients without dementia before the index event. Cognitive assessment, including Clinical Dementia Rating (CDR) scale, 4 Cantonese MiniMental State Examination (MMSE), 5 and the Hong Kong version of the Montreal Cognitive Assessment (MoCA), 6 were performed on subjects at 3 to 6 months (baseline) after the index event to index general cognition. Then subjects were further invited to return for annual follow-up. This study analyzed the data collected ≤3 years.
This substudy included a sample of 72 subjects with cognitive impairment (CDR grade ≥0.5) from the STRIDE study. Clinical diagnoses were made by 2 neurologists specialized in dementia (V.C.T.M. and L.A.). Thirty-six subjects had CDR grade of ≥1 and met the criteria for dementia according to Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision. 7 Thirty-six subjects were diagnosed as mild cognitive impairment on basis of the framework proposed by the International Working Group on mild cognitive impairment 8 : objective cognitive impairment was defined as scores below the established cutoff for impairment on the MMSE or MoCA, 5, 6 and criteria for subjective cognitive complaints and perseveration of daily functioning were evaluated as part of the assessment of CDR rating. 4 In addition, we interviewed the subject's reliable informant or caregiver to obtain information about their cognitive condition before the index event. We excluded subjects with known history of probable AD before the index event, which was defined by the presence of dementia or a history of progressive cognitive decline in the absence of prior stroke/TIA history and relevant cerebrovascular lesions on neuroimaging, fitting the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria. 3 All subjects received 11 C-PiB PET scan. With reference to 11 C-PiB PET findings, 14 PiB-positive subjects were defined as mVCI, whereas 58 PiB-negative subjects were defined as pVCI.
During 3-year follow-up, 13 subjects were lost to follow-up, including 9 deaths (3 pneumonia, 2 renal failure, 1 intracranial hemorrhage, 1 femur fracture, 1 rectum cancer, and 1 autoimmune hemolytic anemia) and 4 dropouts because of poor condition (n=1) or refusal (n=3). Overall, there was no significant difference between subjects with or without completing 3-year follow-up in terms of demographic characteristics, measures of cerebrovascular lesions, global PiB retention, and MMSE score at baseline (Table I in the online-only Data Supplement). Figure 1 shows the study flow.
Cognitive Assessment
Cognitive assessment was performed at baseline and years 1, 2, and 3 after the index event using the CDR, 4 Cantonese MMSE, 5 and the Hong Kong version of the MoCA 6 by trained psychologists blinded to subjects' imaging data. Cognitive domains scores were calculated from the MoCA for memory (scores ranged between 0 and 12), visuospatial (0-4), language (0-5), attention (0-4), and executive functions (0-5) based on a method described previously. 
Medical History
We collected data on basic demography (age, sex, and years of education) and vascular risk factors (smoking, hypertension, hyperlipidemia, diabetes mellitus, atrial fibrillation, ischemic heart disease, and congestive heart failure) using standards described elsewhere during subject's hospitalization for the index event.
1 In addition, we performed assay of ApoE genotyping in 56 subjects using TaqMan genotyping method with TaqMan SNP assay kits (rs429358, Cat. number: 4351379, Assay ID: C_3084793_20; rs7412, Cat. Number: 4351379, Assay ID: C_904973_10) on the ViiA 7 Real-Time PCR System from Thermo Fisher Scientific Inc (Waltham, MA).
Structural Imaging
All subjects received a noncontrast brain computed tomography (CT) within 24 hours of admission. Brain magnetic resonance imaging (MRI) was performed on a subset of 43 subjects within 1 week of hospital admission if the classification of stroke subtype could not be made based on CT and other clinical parameters. MRI scans were acquired with a 1.5-Tesla (T) scanner (Sonata, Siemens Medical System, Erlangen, Germany) or a 3.0-T scanner (Achieva 3.0 T TX Series, Philips Medical System, Best, The Netherlands) using standard protocols. The following sequences were obtained: T1 and T2 weighted, diffusion-weighted imaging, axial gradient echo, axial fluid-attenuated inversion recovery, and time-of-flight MR angiography. Acute ischemic infarcts were defined as hyperintense MRI diffusionweighted imaging lesions with corresponding hypointensity in the apparent diffusion coefficient map or hypodense lesions on CT that were relevant to the acute neurological signs and symptoms. Ischemic lesions were measured in terms of size, location, and laterality according to methods described previously. 1 White matter changes were assessed according to the Age-Related White Matter Changes (ARWMC) scale on axial fluid-attenuated inversion recovery or CT scan. 10 Old small and large infarcts, which were not clinically relevant to the index stroke, were recorded. Old small infarcts were defined as hypodense foci between 3 and 20 mm on CT scan or hypointense lesions with a hyperintense rim on fluid-attenuated inversion recovery and T1-weighted images. 11 The ventricular-brain ratio was used to index global atrophy on axial MRI or CT. 12 Medial temporal lobe atrophy was measured on coronal T1-weighted MRI or CT images using the Scheltens' 5-point (0-4 points) scale. 13 The presence of medial temporal lobe atrophy was defined as a rating of ≥2 points. 13 For subjects with both CT and MRI, ratings were carried out only on MRI. Imaging measures were recorded by a neurologist (W.L.) who was blinded to the clinical information of participants.
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November 2015 scans was 16.8±7.7 months and that between cognitive assessment at baseline and amyloid scan was 11.6±7.4 months. All subjects received a dose of 15 millicurie-PiB intravenously and the brain was imaged at 5, 35, and 60 minutes after injection with 10-minute emission acquisition at each time point using an integrated in-line PET/ CT scanner (BiographTM 16 LSO HI-REZ; CTI/Siemens Inc). The global standard uptake value ratio (SUVR) was calculated using a previously published protocol. 14 We used the global SUVR of PiB retention at 35 to 45 minutes for comparison between groups. 15 In total 72 subjects, the histogram showed that the distribution of the global PiB SUVR was bimodal. Consequently, a hierarchical cluster analysis was performed that yielded a cutoff value of ≥1.5 to classify PiBpositivity. A specialist in nuclear medicine (E.L.), who was blinded to subjects' cognitive and structural imaging data, reviewed all PET images. The institution's ethics committee approved the study and all subjects or proxy provided written informed consent.
Data Analysis
Demographic information and psychometric test performance were compared between the mVCI and pVCI groups. Group comparisons were performed with independent samples t test for normally distributed continuous variables or Mann-Whiney U test for non-normally distributed variables. Comparisons between categorical variables were made using the χ 2 test. Fisher's exact test was used when >20% of the cells had expected counts <5.
After examination of normality in distribution and homogeneity of variance using Shapiro-Wilk test (all P values >0.05), linear mixed models were used to compare longitudinal cognitive changes between the mVCI and pVCI groups on the MMSE and MoCA. The terms of group, time, and group×time were entered as fixed factors. The group×time interaction term represented the relationship between PiB retention status and cognitive changes over time and was treated as the primary outcome of interest in each model. Age and years of education were entered as covariates because of their potential confounding effects on cognitive performance. To eliminate potential bias caused by drop-out subjects, we used repeated measures ANCOVA to do a subgroup analysis in 59 subjects who completed the 3-year followup. ANCOVA was applied to compare test performance and changes between or within groups. Bonferroni correction was used to adjust for type I error for multiple comparisons. To further evaluate the effects of Aβ retention on cognition, linear regression analyses were conducted between the global PiB SUVR with cognitive scores at different time points and the subsequent changes at different stages. Normality of residuals and linearity between dependent variable and predictor was verified. All comparisons and correlations were corrected for age and years of education on an a priori basis. Statistical analyses were performed using IBM SPSS Statistics version 20 for Windows.
Results

Demographic and Clinical Characteristics at Baseline
Characteristics of 72 subjects who entered this longitudinal observational study are presented in 
Cognitive Changes of 3-Year Follow-Up Between mVCI and pVCI
Mini-Mental State Examination
During 3 years of follow-up, the changes in MMSE score over time were significantly different between the mVCI and pVCI groups (group×time interaction, P=0.007; Figure 3 ). In the mVCI group, the MMSE score at year 3 was lower than that of baseline (P=0.020), whereas in the pVCI group, the overall change in MMSE over 3 years was not significant (P=0.208). Between the 2 groups, the mVCI group had lower MMSE score than pVCI group at the end of 3-year followup (P=0.037; Table 2 ). Furthermore, rates of decline in the mVCI group were constant across years (P=0.283), whereas in the pVCI group the cognition declined faster in year 1 but remained relatively static in years 2 and 3 (P=0.028).
Significant difference in the rate of change on the MMSE between the mVCI and pVCI groups was observed in year 3 (P=0.005). The annual rate of decline in mVCI was also faster compared with that of pVCI (P=0.023; Table 2 ).
We conducted an additional analysis in 59 subjects who completed 3-year follow-up using repeated ANCOVA. The main effect of group×time interaction remained significant (P=0.010), and the differences between or within groups were not changed (Table II in 
Montreal Cognitive Assessment
Linear mixed model showed a nonsignificant trend for difference in changes on the MoCA between the mVCI and pVCI groups over time (group×time interaction, P=0.089; Figure  I in the online-only Data Supplement). The average annual decline of mVCI was greater than that in pVCI (−2.5±3.0 versus −0.6±1.6, respectively; P=0.003).
Further analyses were performed on individual MoCA domains. For memory, only mVCI showed a significant decline (P=0.038), whereas the change over 3 years in pVCI was not significant (P=0.760). The different trajectories between the 2 groups (group×time interaction, P=0.014) were associated with a lower memory score in mVCI compared with pVCI at the end of year 3 (2.0±1.2 versus 5.2±2.8, respectively; P=0.008; Figure II in the online-only Data Supplement). There was no difference between these 2 groups on visuospatial function, language, attention, and executive function. 
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The correlation between PiB SUVR and change in visuospatial functions in year 1 was significant (β=-0.311, P=0.023).
Discussion
In this study, we used 11 C-PiB PET to investigate the influence of Aβ deposition on cognitive decline over 3 years in stroke/ TIA patients without known history of AD. We reported for the first time that AD-like Aβ deposition was strongly associated with greater cognitive deterioration after stroke/TIA, especially over the long term. Despite that MMSE scores between pVCI and mVCI subjects were not significantly different in the short term after the index event, the presence of AD-like Aβ deposition predicted worse cognitive decline 3 years later. Such findings were validated by repeating analysis in those with complete 3-year follow-up data to eliminate the potential bias caused by drop-out subjects. Although not as significant as that of MMSE, findings based on MoCA in a subgroup of 60 patients still provided converging evidence on differential trajectories of cognitive progression between the 2 groups.
The finding about the persistent and deteriorative effects of Aβ on cognition after stroke/TIA is consistent with previous PET studies, showing that Aβ deposition predicts conversion to dementia in persons with normal cognition or mild cognitive impairment, [16] [17] [18] and accounts for further cognitive deterioration in patients with advanced AD stages. 17 It suggests that Aβ deposition may have an independent and lasting effect on cognition or more likely, Aβ keeps modulating cognition indirectly by triggering a cascade of downstream events, such as tau formation, glial activation, synaptic dysfunction, and neuronal loss. 19 In our study, different trajectories on cognitive decline between subjects with or without AD-like Aβ deposition were significant in memory function. This finding is compatible with previous reports that memory impairment is the predominant cognitive deficit associated with amyloid burden. In addition, faster decline on other cognitive domains was also associated with increased Aβ deposition, with some reports on visuospatial and executive function. 21, 22 Early change on visuospatial function might serve as a clinical marker for abnormal amyloid pathology. 21, 23 The widespread distribution of Aβ deposition in frontal, temporal, or parietal regions and related cerebral atrophy (ie, hippocampal or frontal atrophy) may contribute to these neuropsychological dysfunctions. 21, 22, 24, 25 We found that among our stroke/TIA subjects without known history of AD, it was difficult to differentiate between those with or without AD-like Aβ deposition at baseline. In our study, the 2 groups did not differ on the level of severity of cognitive impairment, medial temporal lobe atrophy, features of acute ischemic lesions, and burden of chronic small vessel disease. Although detailed neuropsychological assessment may help to differentiate mVCI and pVCI in some patients, detailed assessment may not be applicable or feasible in many of our elderly subjects with low level of education. Overall, our findings highlight the necessary role of amyloid PET in detecting patients with stroke/TIA having abnormal amyloid burden.
Although the mean MMSE scores appeared to be low for our subjects, majority of them (72%) had either mild cognitive impairment (50% with CDR 0.5) or mild dementia (22% with CDR 1), when potential preventive therapies might still be useful. It should be noted that the low MMSE scores appeared to be on par with that reported for the community elderly persons with mild cognitive impairment and mild dementia in the local population with a generally low education level. 26 Among all clinical characteristics, higher proportion of ApoE ε4 allele was found in mVCI subjects, as epidemiological studies from various populations showed the prevalence of ApoE ε4 allele in ≈50% of patients with late-onset Alzheimer's pathology. [27] [28] [29] Mounting experiment evidence suggest that ApoE4 could accelerate Aβ accumulation by increasing aggregation and impairing clearance of Aβ. 30 The strengths of this study are its longitudinal design and the use of both structural and amyloid imaging measuring cerebrovascular lesions and Alzheimer's pathologies in vivo. Several caveats also should be considered when evaluating the present results. First, although this is the largest study to date to investigate the role of Aβ in post stroke/TIA cognitive decline, the sample size of mVCI group is relatively low. Hence, a larger study is needed to confirm our findings. Second, the proportion of drop-out during the 3-year follow-up was high, although the clinical features were comparable between subjects with and without complete 3-year follow-up. Third, 12 subjects with more severe cognitive dysfunction did not perform the MoCA assessment at baseline because the MoCA was too challenging for impaired subjects especially in combination with low level of education. This may partly explain the nonsignificant findings on the MoCA. Finally, a significant proportion of subjects (n=29, 40.2%) did not have MRI. Because hyperacute and small infarcts could not be visualized well by CT, we might have underestimated these lesions in some patients.
In conclusion, findings from our 11 C-PiB PET study illustrate that the presence of Aβ burden predicts a more rapid and severe cognitive decline in patients having cognitive impairment after stroke/TIA. Our findings advocate the need to examine the coexistence of Alzheimer's pathology in patients with cognitive impairment after stroke/TIA and highlight the importance of amyloid PET in the detection of amyloid burden. Early recognition of abnormal Aβ deposition may help identify patients at high risk of long-term cognitive decline for appropriate management and monitoring. Future investigations in patients with milder cognitive impairment or even those with normal cognition after stroke/TIA are warranted to explore the influence of Aβ deposition on delayed cognitive decline in patients with stroke/TIA. 
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